- European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases.
- Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
- Sandoz now has four biosimilars approved in Europe — more than any other company.1
Holzkirchen, June 19, 2017 — Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European …